Objective To explore the clinical effect of Omalizumab combined with Budesonide in the treatment of children with severe bronchial asthma.Methods A total of 86 children with severe bronchial asthma admitted to the First Affiliated Hospital of Xi'an Jiaotong University from July 2022 to June 2023 were selected as the study objects.All the children were divided into the observation group and the control group using the random number table method,with 43 cases in each group.The observation group was treated with Omalizumab combined with Budesonide,and the control group was treated with Budesonide.The incidence of adverse reactions,lung function and levels of inflammatory factors of the two groups were compared.Results After treatment,the levels of forced expiratory volume in one second and forced expiratory volume in one second/forced vital capacity in the observation group were higher than those in the control group(P<0.05).The levels of hypersensitive C-reactive protein,tumor necrosis factor-α and interleukin-6 in the observation group were lower than those in the control group(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Omalizumab combined with Budesonide has good clinical effect in the treatment of severe bronchial asthma.
维普
万方数据